As two NCI-designated comprehensive cancer centers that were collaborative as prior UOl sites, the University of Wisconsin Carbone Cancer Center (UWCCC) and Rutgers Cancer Institute of New Jersey (CINJ) have proven leadership, a robust infrastructure, and a strong record of conducting clinical trials collaboratively. UWCCC and CINJ have, therefore, formed the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance) with a mission to develop and evaluate innovative early phase experimental therapeutic clinical trials in a multi-disciplinary and multi-institutiona model. Scientific strengths include a translational emphasis with biomarker development;pharmacogenomic assessment;genomic assessment and treatment;clinical and tissue imaging;and systems biology. Organizationally, we have formed working groups that leverage scientific expertise and infrastructural strengths from center shared resources to prioritize ET-CTN efforts. Specific niches unique to the WIN-Alliance include strong PK/PD efforts at UWCCC already adding value to CTEP/U01 clinical trials;complementary imaging strengths at UWCCC and CINJ;genomic analysis using the Rutgers University Cell and DNA Repository (RUCDR);and CINJ's relationship with the Institute for Advanced Study's Simons Center for Systems Biology. Over the past five-years UWCCC and CINJ accrued over 4,000 patients on all therapeutic trials, developed 67 center science driven proposals to NCI-CTEP, and accrued a mean of the targeted 100 patients/yr to the UOl supported studies.
The specific aims are to: 1) develop and perform early clinical trials with new ET-CTN sponsored anti-cancer agents;2) leverage and synergize with center programmatic areas of research and cores to translate scientific discoveries from the laboratory into clinical trials;3) develop integrated and integral genomic, pharmacogenomics, pharmacokinetic, and pharmacodynamic biomarkers;4) develop integral and integrated novel approaches to clinical and tissue imaging;and, 5) train and develop young investigators in translational research.

Public Health Relevance

This application will merge two strong prior Phase I (UOl) sites to create the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance). This group, as a synergistic, multidisciplinary and multi-institutional model, will develop and evaluate innovative, early phase experimental therapeutic clinical trials to improve clinical outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
1UM1CA186716-01
Application #
8725876
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (J1))
Program Officer
Ivy, S Percy
Project Start
2014-03-19
Project End
2019-02-28
Budget Start
2014-03-19
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$849,999
Indirect Cost
$127,683
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08903